These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36692911)

  • 1. Expensive Drugs for Rare Diseases: "Canada, We Have a Problem Here".
    Lexchin J
    Healthc Pap; 2023 Jan; 21(1):4-8. PubMed ID: 36692911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expensive Drug Prices for Rare Cancers: Are Patients Truly Benefitting?
    Jenei K; Gyawali B
    Healthc Pap; 2023 Jan; 21(1):44-51. PubMed ID: 36692916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expensive Drugs for Rare Diseases in Canada: What Value and at What Cost?
    Sirrs S; Anderson H; Jiwani B; Lynd LD; Lun E; Nakagawa B; Regier D; Rizzardo S; McFarlane A
    Healthc Pap; 2023 Jan; 21(1):10-26. PubMed ID: 36692912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Federal Funding for Expensive Drugs for Rare Diseases: How Do We Pick and Choose?
    Lexchin J; Sirrs S
    Healthc Policy; 2024 Aug; 19(4):19-26. PubMed ID: 39229659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generic competition in Canada.
    Steele JW
    Pharmacoeconomics; 1994 Nov; 6(5):480-2. PubMed ID: 10155276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can Managed Access Agreements Mitigate Evidentiary, Economic and Ethical Issues with Access to Expensive Drugs for Rare Diseases in the Canadian Context?
    McPhail M; Bubela T
    Healthc Pap; 2023 Jan; 21(1):59-65. PubMed ID: 36692918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis.
    Divino V; DeKoven M; Kleinrock M; Wade RL; Kim T; Kaura S
    Orphanet J Rare Dis; 2016 May; 11(1):68. PubMed ID: 27207271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health Canada's use of its priority review process for new drugs: a cohort study.
    Lexchin J
    BMJ Open; 2015 May; 5(5):e006816. PubMed ID: 25967989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Access, Health Economics, and the Wave of a Magic Wand.
    Stewart DJ; Bradford JP; Batist G
    Curr Oncol; 2022 Feb; 29(2):1176-1189. PubMed ID: 35200599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marketing before patenting: implications for price controls in Canada.
    Lexchin J
    Open Med; 2010; 4(3):e139-42. PubMed ID: 21687333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patentees research and development expenditure in Canada.
    Li S; Tomalin A
    J Pharm Pharm Sci; 2002; 5(1):5-11. PubMed ID: 12042113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expensive Drugs for Rare Diseases in Canada: Time for Action Everywhere and by Everyone.
    Sirrs S; Anderson H; Jiwani B; Lun E; Nakagawa B; Regier D; Rizzardo S; McFarlane A
    Healthc Pap; 2023 Jan; 21(1):74-80. PubMed ID: 36692920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canadians Need Improved Access to Drugs for Rare Diseases, Not More Denial.
    Rawson NSB; Adams J
    Healthc Pap; 2023 Apr; 21(2):4-10. PubMed ID: 37417343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs in Canada? A Review of Submissions to the Canadian Agency for Drugs and Technologies in Health Common Drug Review.
    Balijepalli C; Gullapalli L; Druyts E; Yan K; Desai K; Barakat S; Locklin J
    Clinicoecon Outcomes Res; 2020; 12():445-457. PubMed ID: 32922050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical policies in Canada. Issues and challenges.
    Angus DE; Karpetz HM
    Pharmacoeconomics; 1998; 14 Suppl 1():81-96. PubMed ID: 10186485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Research output of the Canadian pharmaceutical industry: where has all the R&D gone?
    Kalant N; Shrier I
    Healthc Policy; 2006 May; 1(4):21-34. PubMed ID: 19305677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Prices for High Profits?
    Hollis A
    Healthc Pap; 2023 Jan; 21(1):34-37. PubMed ID: 36692914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Comparison of Pharmaceutical Budget Impact Analysis (BIA) Recommendations Amongst the Canadian Patented Medicine Prices Review Board (PMPRB), Public and Private Payers.
    Foroutan N; Tarride JE; Xie F; Mills F; Levine M
    Pharmacoecon Open; 2019 Dec; 3(4):437-451. PubMed ID: 31041614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New Zealand.
    Rawson NSB
    J Popul Ther Clin Pharmacol; 2020 Jun; 27(2):e58-e67. PubMed ID: 32543163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
    Schey C; Milanova T; Hutchings A
    Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.